Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jun 9:373:n1205.
doi: 10.1136/bmj.n1205.

Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial

Michael J Kovacs  1 , Philip S Wells  2 , David R Anderson  3 , Alejandro Lazo-Langner  4 , Clive Kearon  5 , Shannon M Bates  5 , Mark Blostein  6 , Susan R Kahn  6 , Sam Schulman  5 , Elham Sabri  7 , Susan Solymoss  6 , Tim Ramsay  7 , Erik Yeo  8 , Marc A Rodger  6 ; PERIOP2 Investigators
Affiliations
Randomized Controlled Trial

Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial

Michael J Kovacs et al. BMJ. .

Abstract

Objective: To determine the efficacy and safety of dalteparin postoperative bridging treatment versus placebo for patients with atrial fibrillation or mechanical heart valves when warfarin is temporarily interrupted for a planned procedure.

Design: Prospective, double blind, randomised controlled trial.

Setting: 10 thrombosis research sites in Canada and India between February 2007 and March 2016.

Participants: 1471 patients aged 18 years or older with atrial fibrillation or mechanical heart valves who required temporary interruption of warfarin for a procedure.

Intervention: Random assignment to dalteparin (n=821; one patient withdrew consent immediately after randomisation) or placebo (n=650) after the procedure.

Main outcome measures: Major thromboembolism (stroke, transient ischaemic attack, proximal deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral embolism, or vascular death) and major bleeding according to the International Society on Thrombosis and Haemostasis criteria within 90 days of the procedure.

Results: The rate of major thromboembolism within 90 days was 1.2% (eight events in 650 patients) for placebo and 1.0% (eight events in 820 patients) for dalteparin (P=0.64, risk difference -0.3%, 95% confidence interval -1.3 to 0.8). The rate of major bleeding was 2.0% (13 events in 650 patients) for placebo and 1.3% (11 events in 820 patients) for dalteparin (P=0.32, risk difference -0.7, 95% confidence interval -2.0 to 0.7). The results were consistent for the atrial fibrillation and mechanical heart valves groups.

Conclusions: In patients with atrial fibrillation or mechanical heart valves who had warfarin interrupted for a procedure, no significant benefit was found for postoperative dalteparin bridging to prevent major thromboembolism.

Trial registration: Clinicaltrials.gov NCT00432796.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the Canadian Institute of Health Research and Pfizer for the submitted work; SSc has received honoraria from Alnylam, Boehringer Ingelheim, Bayer HealthCare, Daiichi Sankyo, Pfizer, and Sanofi, and research support from Boehringer Ingelheim and Octapharma. None of these have any connection with the study. SMB has received consultancy fees from Leo Pharma Canada. PSW declares honoraria from Bayer Healthcare, Janssen, Sanofi, Medscape, Servier Canada, Pfizer, BMS, WebMd and grant fees from Bayer Healthcare, Pfizer/BMS in the last 3 years outside the submitted work. There are no other conflicts of interest.

Figures

Fig 1
Fig 1
PERIOP2 bridging study design. Screening visits occurred between 30 days and five days before planned procedure, and randomisation (R) occurred on the day of procedure (day 0) or within 24 hours of procedure (day+1) when haemostasis was achieved (no earlier than 30 minutes after procedure). INR=international normalised ratio
Fig 2
Fig 2
Screening, randomisation, and follow-up of PERIOP2 bridging study
See this image and copyright information in PMC

References

    1. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-11. 10.1056/NEJM199705223362107 - DOI - PubMed
    1. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013;368:2113-24. 10.1056/NEJMra1206531 - DOI - PubMed
    1. Douketis JD, Spyropoulos AC, Spencer FA, et al. . Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 suppl):e326S-e350S. 10.1778/chest.11-2298 - DOI - PMC - PubMed
    1. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 2016;14:875-85. 10.1111/jth.13305. - DOI - PubMed
    1. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007;5:2211-8. 10.1111/j.1538-7836.2007.02729.x. - DOI - PubMed

Publication types

Associated data